Portuguese 
English 
Spanish 
3 min of reading 
0 comments 
The measure published in the Official Gazette of the Union blocks the sale, distribution, use, and advertising of cannabis-derived products without sanitary authorization
A regulatory decision with significant impact was recently published by the National Health Surveillance Agency, attracting national attention. Anvisa prohibited the sale, distribution, use, and promotion of cannabis-based products linked to the brands Biocase and Allandiol. The measure was published in the Official Gazette of the Union on Monday, May 11, 2026. The decision affects the products Allandiol Forte Black 1:1 and Allandiol Full Spectrum 300 mg, manufactured by Instituto Alma Viva Ltda. The move occurred after the agency identified the absence of sanitary registration and lack of an Operating Authorization, known as AFE.
Cannabis-based products come under inspection’s radar
The restriction determined by Anvisa covers cannabis-derived medicines that, according to the agency, were offered without sanitary approval. Products for medicinal purposes must follow specific rules before reaching the consumer. The agency informed that the mentioned items did not have a valid registration for manufacturing, distribution, or commercialization. Therefore, the measure suspended not only the sale but also the use, advertising, and any form of promotion of the products. The case reinforces Anvisa’s action regarding medicines advertised as therapeutic without official authorization.
Irregular disclosure identified online
The inspection also pointed out irregularities in digital channels linked to the company. According to Anvisa, the products were promoted on the company’s website and its Instagram profile. In these spaces, alleged therapeutic benefits associated with cannabis-based products were presented. These effects, however, did not have sanitary approval recognized by the regulatory agency. The advertising was included in the suspension published in the Official Gazette of the Union.
-
China ‘decrees’ the end of diesel: new maritime engine of 1,953 tons and 64,500 kW runs on more than 95% methanol, uses 5G technology, and could forever change the giant 16,000-container ships
-
Cold air mass advances through the Atlantic, drops temperatures in the Southeast, and may even surprise the Northeast with heavy rain in Bahia and minimums below 10ºC in the interior.
-
Government releases new shoulder function on roads: side lane gains solar plants capable of supplying 100% of road operation using tolls, roofs, and technical areas without altering the asphalt in Kiato, Greece
-
Capable of hitting vessels hundreds of kilometers away at supersonic speed and drastically reducing enemy reaction time, the BrahMos arrives in Vietnam under an agreement that includes pilot training by India and aims to create a deterrent arc in front of the disputed islands with China.
Absence of authorization expands sanitary alert
Anvisa highlighted that the lack of sanitary registration prevents the regular commercialization of the products. The absence of AFE also indicates that the company did not have authorization to manufacture or sell these medicines. Consequently, the agency deemed it necessary to stop the circulation of the items in the market. The measure seeks to prevent consumers from accessing products without adequate regulatory proof. This point is central because medicines must undergo technical evaluation before being made available to the public.
Instituto Alma Viva contests the decision
After the resolution’s publication, Instituto Alma Viva issued a statement to g1. The institution stated it received the decision with surprise. The institute declared that there had been a confusion between distinct companies belonging to the same business group. The entity also presented itself as a regular center for teaching, research, and assistance in mental health. Finally, it affirmed that it does not commercialize medicines.
Regulation reinforces control over medicinal cannabis
Anvisa’s decision amplifies the alert about cannabis-derived products sold or promoted without official authorization. Currently, the commercialization of this type of item depends on specific sanitary rules. Companies must prove regularity before advertising or selling products for therapeutic purposes. The measure also shows that the internet has definitively entered the focus of sanitary inspection. This scenario reinforces the role of regulation in consumer protection.
The future of inspection over cannabis-derived products
Anvisa’s action indicates that cannabis-based medicines must follow formal requirements before circulating in the Brazilian market. Products without registration, without authorization, and with irregular therapeutic promotion are likely to face new regulatory barriers. Digital inspection should also gain strength, as offers on websites and social media were cited in the case.
Given this scenario, how to balance access, sanitary safety, and control over cannabis-based products in Brazil?
Be the first to react!